Advertisement
AMPH vs EBS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMPH is a Buy and EBS is a StrongBuy.
AMPH in +6.22% Uptrend, growing for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where AMPH advanced for three days, in 254 of 326 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on AMPH as a result. In 61 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for AMPH just turned positive on October 30, 2026. Looking at past instances where AMPH's MACD turned positive, the stock continued to rise in 34 of 46 cases over the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The 10-day RSI Indicator for AMPH moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator moved out of overbought territory. In 27 of the 47 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 69 cases where AMPH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
AMPH broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AMPH entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. AMPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.578) is normal, around the industry mean (6.379). P/E Ratio (16.374) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.640) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.522) is also within normal values, averaging (183.387).
The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
EBS in +4.27% Uptrend, growing for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where EBS advanced for three days, in 214 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 60 cases where EBS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EBS as a result. In 81 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EBS turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 40 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
EBS moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for EBS crossed bearishly below the 50-day moving average on November 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EBS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for EBS entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.910) is normal, around the industry mean (6.379). P/E Ratio (-1.782) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.160) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.493) is also within normal values, averaging (183.387).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. EBS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EBS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
AMPH | EBS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 35 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 57 Fair valued | 39 Fair valued | |
PROFIT vs RISK RATING 1..100 | 84 | 100 | |
SMR RATING 1..100 | 69 | 97 | |
PRICE GROWTH RATING 1..100 | 36 | 60 | |
P/E GROWTH RATING 1..100 | 13 | 98 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EBS's Valuation (39) in the Biotechnology industry is in the same range as AMPH (57) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to AMPH’s over the last 12 months.
AMPH's Profit vs Risk Rating (84) in the Pharmaceuticals Other industry is in the same range as EBS (100) in the Biotechnology industry. This means that AMPH’s stock grew similarly to EBS’s over the last 12 months.
AMPH's SMR Rating (69) in the Pharmaceuticals Other industry is in the same range as EBS (97) in the Biotechnology industry. This means that AMPH’s stock grew similarly to EBS’s over the last 12 months.
AMPH's Price Growth Rating (36) in the Pharmaceuticals Other industry is in the same range as EBS (60) in the Biotechnology industry. This means that AMPH’s stock grew similarly to EBS’s over the last 12 months.
AMPH's P/E Growth Rating (13) in the Pharmaceuticals Other industry is significantly better than the same rating for EBS (98) in the Biotechnology industry. This means that AMPH’s stock grew significantly faster than EBS’s over the last 12 months.
| AMPH | EBS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 57% | N/A |
| Stochastic ODDS (%) | 2 days ago 59% | 2 days ago 78% |
| Momentum ODDS (%) | 2 days ago 75% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 88% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 87% |
| Advances ODDS (%) | 3 days ago 78% | 3 days ago 80% |
| Declines ODDS (%) | 20 days ago 67% | 7 days ago 86% |
| BollingerBands ODDS (%) | 2 days ago 67% | N/A |
| Aroon ODDS (%) | 2 days ago 63% | 2 days ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMPH’s FA Score shows that 1 FA rating(s) are green while EBS’s FA Score has 0 green FA rating(s).
- AMPH’s FA Score: 1 green, 4 red.
- EBS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMPH’s TA Score shows that 3 TA indicator(s) are bullish while EBS’s TA Score has 2 bullish TA indicator(s).
- AMPH’s TA Score: 3 bullish, 5 bearish.
- EBS’s TA Score: 2 bullish, 6 bearish.
Price Growth
AMPH (@Pharmaceuticals: Generic) experienced а +7.15% price change this week, while EBS (@Pharmaceuticals: Generic) price change was -3.20% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.
Reported Earning Dates
AMPH is expected to report earnings on Mar 04, 2027.
EBS is expected to report earnings on Mar 03, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.20% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
AMPH and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMPH has been loosely correlated with AMRX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if AMPH jumps, then AMRX could also see price increases.
| Ticker / NAME | Correlation To AMPH | 1D Price Change % | ||
|---|---|---|---|---|
| AMPH | 100% | -1.09% | ||
| AMRX - AMPH | 45% Loosely correlated | +0.47% | ||
| IXHL - AMPH | 40% Loosely correlated | -8.22% | ||
| EBS - AMPH | 40% Loosely correlated | -0.82% | ||
| VTRS - AMPH | 36% Loosely correlated | +1.76% | ||
| ANIP - AMPH | 33% Poorly correlated | +5.10% | ||
More | ||||
EBS and
Correlation & Price change
A.I.dvisor indicates that over the last year, EBS has been loosely correlated with AMPH. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then AMPH could also see price increases.
| Ticker / NAME | Correlation To EBS | 1D Price Change % | ||
|---|---|---|---|---|
| EBS | 100% | -0.82% | ||
| AMPH - EBS | 41% Loosely correlated | -1.09% | ||
| SIGA - EBS | 40% Loosely correlated | -3.99% | ||
| COLL - EBS | 40% Loosely correlated | -0.97% | ||
| XERS - EBS | 33% Loosely correlated | -0.19% | ||
| VTRS - EBS | 32% Poorly correlated | +1.76% | ||
More | ||||